Post-Finasteride Adverse Effects in Male Androgenic Alopecia: A Case Report of Vitiligo
Motofei et al., 2017
“Our patient developed vitiligo at 2 months following the termination of finasteride therapy - presumed in our opinion as a post-finasteride syndrome.”
A 52 year old patient had enrolled in a sample group with an inclusion criteria of normal plasma hormone levels as well as good sexual function and the absence of psychiatric impairment per validated measures. He received finasteride 1mg per day for four months.
The patient developed persistent sexual dysfunction, depression, gynecomastia and generalised vitiligo after using finasteride. These remained unchanged at the end of a three-month period of observation.
They determined this constituted PFS. The authors concluded that it is unclear whether vitiligo is a rare adverse effect in PFS, or whether it is underestimated due to the lack of vigilance in monitoring and reporting after discontinuation of treatment.
